PE20151947A1 - Reduccion de la respuesta proinflamatoria - Google Patents

Reduccion de la respuesta proinflamatoria

Info

Publication number
PE20151947A1
PE20151947A1 PE2015001982A PE2015001982A PE20151947A1 PE 20151947 A1 PE20151947 A1 PE 20151947A1 PE 2015001982 A PE2015001982 A PE 2015001982A PE 2015001982 A PE2015001982 A PE 2015001982A PE 20151947 A1 PE20151947 A1 PE 20151947A1
Authority
PE
Peru
Prior art keywords
pro
inflammatory response
reduction
composition
inflammatory
Prior art date
Application number
PE2015001982A
Other languages
English (en)
Inventor
Gabriele Gross
Dirk Hondmann
Tol Erick A F Van
Marieke H Schoemaker
Teartse Tim Lambers
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PE20151947A1 publication Critical patent/PE20151947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente divulgacion proporciona un procedimiento para suprimir una respuesta proinflamatoria mediante la administracion de una composicion que comprende peptidos seleccionados a partir de un hidrolizado de caseina. Dicha composicion puede reducir los niveles de citoquinas proinflamatorias y puede ser un tratamiento para enfermedades inflamatorias, especialmente la diabetes tipo 1. Preferiblemente, el hidrolizado consiste en peptidos con un peso molecular mayor a 500 Da
PE2015001982A 2013-03-15 2014-03-11 Reduccion de la respuesta proinflamatoria PE20151947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/838,539 US9352020B2 (en) 2013-03-15 2013-03-15 Reducing proinflammatory response

Publications (1)

Publication Number Publication Date
PE20151947A1 true PE20151947A1 (es) 2016-01-20

Family

ID=50391507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001982A PE20151947A1 (es) 2013-03-15 2014-03-11 Reduccion de la respuesta proinflamatoria

Country Status (17)

Country Link
US (1) US9352020B2 (es)
EP (1) EP2968437B1 (es)
CN (1) CN105142658B (es)
AR (1) AR095336A1 (es)
AU (1) AU2014237027C1 (es)
BR (1) BR112015018259A2 (es)
CA (1) CA2905820A1 (es)
ES (1) ES2821750T3 (es)
HK (1) HK1216995A1 (es)
MX (1) MX2015011938A (es)
MY (1) MY177369A (es)
PE (1) PE20151947A1 (es)
PH (1) PH12015502102A1 (es)
RU (1) RU2015139359A (es)
SG (1) SG11201505693WA (es)
TW (1) TW201505647A (es)
WO (1) WO2014150571A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4194001A1 (en) * 2015-04-22 2023-06-14 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
US20170020950A1 (en) * 2015-07-23 2017-01-26 Mead Johnson Nutrition Company Methods for modulating kinases
JP2018532417A (ja) * 2015-11-09 2018-11-08 エム・ジェイ・エヌ ユー．エス． ホールディングス リミテッド ライアビリティー カンパニー 酪酸塩を含む栄養組成物およびその使用
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US20180160714A1 (en) * 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
US20190208807A1 (en) * 2018-01-05 2019-07-11 Mead Johnson Nutrition Company Nutritional compositions containing milk-derived peptides and uses thereof
CN108967557A (zh) * 2018-09-29 2018-12-11 贝因美（杭州）食品研究院有限公司 一种婴儿配方食品及其制备方法
CN110204595A (zh) * 2019-06-04 2019-09-06 海普诺凯营养品有限公司 一种具有调节b淋巴细胞活性的羊乳酪蛋白水解肽及其制备方法
GB2608587A (en) * 2021-06-25 2023-01-11 Mjn Us Holdings Llc Use of extensively hydrolysed protein
CN114989247B (zh) * 2022-04-27 2024-04-02 中南林业科技大学 一种牦牛奶渣抗缺氧或低氧、抗疲劳肽及其制备方法和应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
GB1475624A (en) 1974-07-22 1977-06-01 Toyama Chemical Co Ltd Polypeptide
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A0 (fi) 1989-08-28 1990-08-17 Milupa Ag Protein-, peptid- och aminosyrablandningar med optimerad aminosyrasammansaettning samt deras anvaendning foer framstaellning av naering foer prematur- och dibarn samt av tillsatser till modersmjoelk.
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
KR100321543B1 (ko) 1991-01-24 2002-09-12 마르텍 코포레이션 미생물-기원오일혼합물및이의용도
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
GB9310472D0 (en) 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
ATE442585T1 (de) 1994-11-04 2009-09-15 A2 Corp Ltd Selektionsverfahren für nicht-diabetogene milch oder milchprodukte sowie hierdurch erfasste milch oder milchprodukte
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
IT1277964B1 (it) 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
WO1998002165A1 (en) 1996-07-17 1998-01-22 Nutracorp Scientific, Inc. Appetite suppression
KR100221124B1 (ko) 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
ATE320724T1 (de) 1999-12-30 2006-04-15 Kerry Group Services Ltd Aufbaupräparat, das kohlenhydrat- und peptidmaterial enthält und sein gebrauch als energieergänzung nach oder während körperlicher übung oder als metabolischer nährstoff für die orale verabreichung
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
TWI268138B (en) 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
AU3409001A (en) 2000-06-28 2002-01-08 Fuji Abrasive Works Novel inulin synthase and process for producing inulin by using the same
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
WO2002032231A1 (en) 2000-10-19 2002-04-25 Edens, Luppo Protein hydrolysates
AU2002320407A1 (en) 2001-07-10 2003-01-29 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
ES2291493T3 (es) 2001-07-18 2008-03-01 Dsm Ip Assets B.V. Proceso de hidrolisis de las proteinas de la leche.
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
WO2003044044A1 (fr) 2001-11-21 2003-05-30 Morinaga Milk Industry Co., Ltd. Nouveau peptide exerçant un effet inhibiteur d'angiotensine convertase
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
ES2540926T3 (es) 2002-06-04 2015-07-14 Dsm Ip Assets B.V. Hidrolizado de proteínas rico en tripéptidos
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
AU2003264256A1 (en) 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
JPWO2004050118A1 (ja) 2002-11-29 2006-03-30 森永乳業株式会社 プロテアーゼ阻害剤
WO2004061108A1 (ja) 2002-12-29 2004-07-22 Toudai Tlo, Ltd. アディポネクチン受容体及びそれをコードする遺伝子
BRPI0409536A (pt) 2003-05-05 2006-04-18 Unilever Nv processo para a preparação de um produto de caseìna hidrolisada, produtos de caseìna hidrolisada e produtos alimentìcios
EP1663298B1 (en) 2003-09-23 2019-07-17 DSM IP Assets B.V. Use of proline specific endoproteases to hydrolyse peptides and proteins
DK1721612T3 (da) 2003-10-24 2009-06-02 Nutricia Nv Immunmodulerende oligosaccharider
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
AU2005207891B2 (en) 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
EP1753443A1 (en) 2004-05-27 2007-02-21 Campina Nederland Holding B.V. Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR100560127B1 (ko) 2004-09-04 2006-03-13 한국기초과학지원연구원 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
CN101179954A (zh) 2004-11-12 2008-05-14 荷兰纽迪希亚公司 用于快速减弱炎症反应的含有蛋白质和脂质的食品组合物
KR101331777B1 (ko) 2004-12-23 2013-11-21 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ-ｉｖ를 억제하는 펩타이드가 풍부한 단백질가수분해물 및 이의 용도
EP1838172B1 (en) 2005-01-18 2010-12-15 DSM IP Assets B.V. Novel nutraceutical compositions
US8129337B2 (en) 2005-02-03 2012-03-06 Dsm Ip Assets B.V. Compositions comprising epigallocatechin gallate and protein hydrolysate
DE602006005788D1 (de) 2005-02-09 2009-04-30 Unilever Nv Lebensmittelprodukte mit hydrolysierten milchfeststoffen mit verbessertem geschmack
JP2008539203A (ja) 2005-04-28 2008-11-13 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助組成物
AU2006239561B2 (en) 2005-04-28 2010-09-16 Unilever Plc Peptides having a health benefit and compositions comprising them
US20090074893A1 (en) 2005-04-29 2009-03-19 Campina Nederland Holding B.V. Antiviral peptides
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US20090203592A1 (en) 2005-07-01 2009-08-13 N.V. Nutricia Infant nutrition with hydrolised proteins
GB0523806D0 (en) 2005-11-23 2006-01-04 Micromass Ltd Mass spectrometer
WO2007064208A1 (en) 2005-11-30 2007-06-07 Campina Nederland Holding B.V. Use of a protein hydrolysate for enhancing activity of glucagon-like peptide-1
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ES2366034T3 (es) 2005-12-23 2011-10-14 N.V. Nutricia Composición que comprende ácidos grasos poliinsaturados, proteínas, manganeso y/o molibdeno y nucleósidos/nucleótidos para el tratamiento de la demencia.
US20100167979A1 (en) 2006-02-09 2010-07-01 Calpis Co. Ltd Rheumatoid arthritis-preventive agent for oral intake
WO2007107587A2 (en) 2006-03-22 2007-09-27 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
CN101420867A (zh) 2006-04-12 2009-04-29 帝斯曼知识产权资产管理有限公司 新颖的营养药物组合物
CN101426513B (zh) 2006-04-21 2013-05-01 株式会社明治 含有肽作为有效成分的组合物
KR20130140215A (ko) 2006-04-28 2013-12-23 유키지루시 메그밀크 가부시키가이샤 펩티드
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
CN101795579A (zh) 2006-08-04 2010-08-04 Shs国际有限公司 无蛋白配方
EP2049091B1 (en) 2006-08-09 2010-12-29 DSM IP Assets B.V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
JP5313906B2 (ja) 2007-04-12 2013-10-09 インダストリー−アカデミック コーペレイション ファウンデイション， ヨンセイ ユニバーシティ 亜鉛が含有された金属酸化物磁性ナノ粒子を含む磁気共鳴映像剤
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2008147562A2 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2008153429A2 (en) 2007-06-11 2008-12-18 Uniwersytet Jagiellonski A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
WO2009033785A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
RU2543634C2 (ru) * 2008-06-13 2015-03-10 Н.В. Нютрисиа Питание, стимулирующее иммунную систему
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2253324A1 (en) 2009-04-30 2010-11-24 Consejo Superior De Investigaciones Cientificas Use of a casein-derived peptide and compositions thereof as antihypertensive
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
EP2332428B1 (en) 2009-12-04 2014-08-20 MJN U.S. Holdings LLC Nutritional Formulation comprising a cow's milk peptide-containing hydrolysate and/or peptides derived thereof for tolerance induction
NZ601141A (en) 2010-01-19 2014-07-25 Abbott Lab Nutritional formulas containing synbiotics
JP5715117B2 (ja) 2010-02-24 2015-05-07 森永乳業株式会社 摂食障害治療剤
EP2658547A1 (en) * 2010-12-31 2013-11-06 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
EP2968437A1 (en) 2016-01-20
US20140271554A1 (en) 2014-09-18
MY177369A (en) 2020-09-14
CN105142658B (zh) 2018-10-23
AR095336A1 (es) 2015-10-07
ES2821750T3 (es) 2021-04-27
AU2014237027A1 (en) 2015-08-13
CN105142658A (zh) 2015-12-09
CA2905820A1 (en) 2014-09-25
WO2014150571A1 (en) 2014-09-25
US9352020B2 (en) 2016-05-31
RU2015139359A (ru) 2017-04-24
EP2968437B1 (en) 2020-07-29
AU2014237027B2 (en) 2019-02-28
PH12015502102B1 (en) 2016-01-11
SG11201505693WA (en) 2015-08-28
PH12015502102A1 (en) 2016-01-11
HK1216995A1 (zh) 2016-12-16
MX2015011938A (es) 2015-12-01
NZ710033A (en) 2020-09-25
AU2014237027C1 (en) 2019-06-06
TW201505647A (zh) 2015-02-16
BR112015018259A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
PE20151947A1 (es) Reduccion de la respuesta proinflamatoria
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112016024319A2 (pt) métodos para aumentar os níveis de hemácias e tratar anemia falciforme
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
BR112015001756A2 (pt) aparelho de válvula protética com várias estruturas e métodos
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112013018286A2 (pt) derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
PH12015502100A1 (en) Reducing the risk of autoimmune disease
BR112016009429A2 (pt) Filme de xiloglucano
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
AR095661A1 (es) Método de activación de adiponectina mediante hidrolizado de caseína

Legal Events

Date Code Title Description
FA Abandonment or withdrawal